STATE UNIVERSITY

«UZHHOROD NATIONAL UNIVERSITY»

MEDICAL FACULTY №2

Department of the Physiology and Pathophysiology

Palamarchuk O.S., Patskun S.V., Nemesh M.I., Sheiko N.I., Feketa V.P., Kaliy V.V.

PULMONARY FUNCTION TESTING

METHODICAL INSTRUCTIONS

for practical classes and self-study on Physiology and Pathophysiology

for medical students

of Faculty of Medicine №2, specialty 222 “Medicine”

Uzhhorod

2023

УДК 616.24-072.7(076)
П 14

Pulmonary function testing: methodical instructions for practical classes and self-study on Physiology and Pathophysiology for medical students of Faculty of Medicine №2, specialty 222 “Medicine” / Palamarchuk O.S., Patskun S.V., Nemesh M.I., Sheiko N.I., Feketa V.P., Kaliy V.V. : SHEI “UzHNU”, p. 58. 2023.

Educational and methodical recommendations on the subject “Clinical Physiology” are designed to teach students the basics of spirometry. The purpose – to provide explain the technique of performing spirometry, the interpretation of results in normal and pathological conditions, and provide examples of MCQs with explanation for preparing for “Krok-2” and mastering the subject by students’ preparation for practical classes in clinical physiology.

Editors:

Palamarchuk O.S. - PhD MD, associate professor of the physiology and pathophysiology department of medical disciplines medical faculty №2.

Patskun S.V. - PhD MD, associate professor of the physiology and pathophysiology department of medical disciplines medical faculty №2.

Nemesh M.I. - PhD MD, associate professor of the physiology and pathophysiology department of medical disciplines medical faculty №2.

Sheiko N.I. - assistant of the physiology and pathophysiology department of medical faculty №2.

Feketa V.P. – DBSc, prof. head of the physiology and pathophysiology department of medical faculty №2.

Kaliy V.V. – DMSc, prof. Dean of the Medical faculty №2.

Reviwers:

Krichfalushii O.P. - PhD MD, associate professor of the physiology and pathophysiology department of Medical Faculty №2.

Moskal O.M. - PhD MD, associate professor of the internal medicine department of Medical Faculty №2.

Approved and recommended for publication at the meeting of the academic council of the Faculty of Medicine 2 (Minutes №2 September 21, 2023)

CONTENT

Pulmonary function testing	4
Spirometry	4
Spirometer calibration	8
Procedure for performing spirometry	10
Normal lung function	13
Spirometry interpretation	15
Bronchodilator testing	19
Spirometry in upper airway obstruction	20
Diffusing capacity physiology	24
Lung volumes	27
Techniques for measuring lung volumes	30
Bronchial provocation tests	32
MCQs with explanation	34
References	58

PULMONARY FUNCTION TESTING

Pulmonary function tests (PFTs) are an integral part of diagnosing and managing patients with respiratory disease. PFTs play an important role in respiratory medicine but they are only one piece of the puzzle and are not diagnostic of any given disease: many pathologic processes share similar pulmonary function patterns. PFTs are most useful when interpreted in conjunction with other clinical information including history, physical examination, imaging studies, and laboratory data.

PFTs provide clinically useful information under the following conditions:

1) measurements are accurate and precise,

2) patient data are compared with high-quality reference values appropriate for the patient population,

3) the interpretation is made according to a standardized interpretation strategy,

4) the report is configured to highlight important data and to avoid interpretive errors.

The commonly performed and most clinically useful PFTs are discussed: spirometry, diffusing capacity, lung volume tests, tests of respiratory muscle strength, and bronchial provocation tests.

SPIROMETRY

Spirometry is a simple and non-invasive test used to assess lung function.

It measures lung volumes and airflow rates to evaluate the presence and severity of respiratory conditions.

Spirometry is often performed in hospitals, clinics, and pulmonary function laboratories.



Figure 1. Spirometry

Indications for Spirometry:

- Evaluate respiratory symptoms, signs, abnormal laboratory or radiographic findings
- Assist in diagnosing respiratory diseases
- Monitor respiratory disease activity and response to therapy
- Determine respiratory disease prognosis
- Evaluate the pulmonary effects of occupational, environmental, and drug exposures
- Provide objective assessment of impairment or disability
- Evaluate risk prior to lung resection surgery
- Assist in smoking-cessation efforts

Contraindications for Spirometry:

- Inability to follow technician instructions due to altered mental status or patient unwillingness
- Subjective discomforts such as pain and nausea

If any of the following have occurred recently, then it may be better to wait until the patient has fully recovered before carrying out spirometry.

- Haemoptysis of unknown origin
- Pneumothorax

- Unstable cardiovascular status, recent myocardial infarction or pulmonary embolism
- Thoracic, abdominal or cerebral aneurysms
- Recent eye surgery
- Acute disorders affecting test performance, such as nausea or vomiting
- Recent thoracic or abdominal surgical procedures

Testing should be terminated if the patient develops significant lightheadedness or syncope. Testing should also be terminated if sequential spirometric measurements show a greater than 20% reduction in FEV_1 that is not explained by procedural problems, suggesting maneuver induced bronchoconstriction.

Infection control

Hands must be washed between patients. Bacterial–viral filters should be used for all patients and thrown away by the patient at the end of testing. If an infectious patient requires testing, this should be performed at the end of the session and the equipment should be stripped down and sterilized/parts replaced (depending on what is being used) before being used again.

Spirometry Measurements:

1. Forced Vital Capacity (FVC):
    - FVC represents the total volume of air forcefully exhaled after a full inhalation.
    - It measures the maximum amount of air a person can exhale from the lungs.
2. Forced Expiratory Volume in One Second (FEV_1):
    - FEV_1 measures the volume of air forcefully exhaled in the first second during the FVC maneuver.
    - It provides information about the rate at which air can be expelled from the lungs.
3. FEV_1/FVC Ratio:
    - The FEV_1/FVC ratio is the ratio of FEV_1 to FVC.

- It helps assess the presence of airflow limitation.
- A reduced FEV_1/FVC ratio is indicative of obstructive lung diseases such as asthma or chronic obstructive pulmonary disease (COPD).

4. Peak Expiratory Flow Rate (PEFR):
   - PEFR measures the maximum speed of airflow during a forced exhalation.
   - It is often measured using a peak flow meter, a handheld device.
   - PEFR is useful for monitoring asthma and assessing changes in lung function.
5. Forced Expiratory Flow (FEF):
   - FEF represents the flow rate during the middle portion of the forced expiration.
   - Different FEF measurements, such as $FEF_{25\%–75\%}$, $FEF_{50\%}$, and $FEF_{75\%}$, assess airflow at specific points during expiration.
   - These measurements can help detect abnormalities in smaller airways.
6. Slow Vital Capacity (SVC):
   - SVC measures the maximum volume of air exhaled slowly and completely after a full inhalation.
   - It is primarily used to evaluate restrictive lung diseases or neuromuscular disorders affecting respiratory muscles.

Figure 2. Peak-flow meter



PEF reflects the caliber of the large airways and is highly effort dependent. Although PEF is attractive because it can be measured using inexpensive handheld devices, it is a more variable measure than FEV_1 and the correlation between PEF and FEV_1 in patients with airway obstruction is poor. Neither $FEF_{25\%–75\%}$ or PEF offers any advantage over FEV_1.

Equipment:

The most common type of spirometer is the flow-sensing spirometer, which uses a flow sensor to measure airflow.

Other equipment includes a mouthpiece or face mask for the patient, a tubing system, 3-L syringe, and a computer or electronic display to record and analyze data.

SPIROMETER CALIBRATION

To achieve accurate and reproducible spirometry results, measurements from your spirometer should be regularly checked against a precision calibration syringe. Calibration is the procedure for establishing the relationship between sensor-determined values of flow or volume, and the actual flow or volume, using a validated 3-L calibration syringe. Calibration should be performed daily or prior to use.

The 3L syringe provides an easy and reliable method of calibrating and measuring the accuracy of respiratory volume-measuring equipment in the field. One calibrated 3L syringe is normally supplied with each new instrument and provides you with a fixed mechanical standard. Flow volume verification is performed by injecting a known volume (typically three liters) at various flow rates (½, 3, and 6 second intervals). Achieving accurate volumes at different flow rates demonstrates that volume measurement is independent of the flow rate. This is important because pulmonary function tests require accurate volume measurements at different flow rates that the spirometer will measure from patients.

<u>Calibration performing:</u> Be sure to position the syringe on a flat, level surface. Use one hand to gently stabilize the syringe and the other to push or pull the piston rod directly in/out of the syringe. If an in-line filter is used in spirometry testing, then it must also be used during recalibrations and verifications. Start with the syringe piston completely pulled out, then smoothly push it in until you gently bump the piston head against the inside of the syringe. Try to have a slow, consistent motion, and do not start or stop too abruptly. However, if you’re going to err on one side or the other, it's better to start fast and then slow down as you get towards the end of the time period of the stroke. A complete inspiratory syringe stroke is the exact opposite. Start with the syringe piston completely pushed in, then pull it out smoothly until you gently bump the piston head against the inside of the syringe.



Figure 3. Spirometer Calibration

PROCEDURE FOR PERFORMING SPIROMETRY

Spirometry is commonly performed in the primary care setting and can be completed in less than 15 minutes. The volume accuracy of the spirometer should be checked at least daily with a 3-L syringe. The instrument should display both flow-volume and volume-time tracings, and inspections of these tracings are needed for optimal quality control.

Step 1. Explain the procedure to the patient and ensure they understand what is expected.

Step 2. Instruct the patient to sit upright and comfortably, with their feet flat on the floor.

Step 3. Apply nose clips to the patience's nose, it helps prevent patients from inhaling or exhaling through the nose during spirometry.

Step 4. Instruct the patient to take a deep breath and exhale forcefully into the spirometer mouthpiece or face mask.

Step 5. Encourage the patient to exhale as long and forcefully as possible to achieve accurate and reproducible results.

Typically, multiple maneuvers are performed to ensure consistency and reliability of the measurements.

The spirometer will generate a flow-volume loop and provide numerical values such as forced vital capacity (FVC) and forced expiratory volume in one second (FEV_1).

Spirometry Acceptability (Within-Maneuver) Criteria

1. Good start of test

a. Sharp take-off without hesitation

b. Extrapolated volume < 5% or 0.15 L, whichever is greater (FVC – 100%, x – 5%. Example 5l – 100%, x – 5% = 5*5/100=0.25l or 250 ml)

2. Meet end-of-test criteria

a. Complete exhalation to RV

b. Plateau on volume-time curve

c. Exhalation time ≥ 6 seconds (3 sec for children)

3. Absence of artifacts

a. Cough, especially during first second of exhalation

b. Glottis closure

c. Hesitation or submaximal effort

d. Air leak

e. Obstructed mouthpiece



Examples of flow-volume (*left*) and volume-time (*right*) tracings for a healthy subject are illustrated. FEV_1, forced expiratory volume in 1 second.

Figure 4. Example of spirogram in norm.

An adequate FVC maneuver requires:

1) maximal inspiration to total lung capacity (TLC);

2) an abrupt, maximally forceful exhalation;

3) exhalation continuing to residual volume.

In older patients and in patients with airway obstruction, an unforced or slow vital capacity (SVC) may be useful. In these patients, the SVC may be larger than the FVC due to dynamic air trapping with the forced maneuver. The largest vital capacity (VC) obtained should be used for interpretation.

Interpreting Spirometry Results

The initial step in spirometry interpretation is to assess test acceptability and repeatability. The American Thoracic Society/European Respiratory Society (ATS/ ERS) Task Force on Standardization of Lung Function Testing provides clear guidelines for assessing test acceptability and repeatability. An acceptable study requires the visual examination of each individual effort to determine whether specific within-maneuver criteria are met. This should include direct inspection of both the volume-time and the flow-volume tracings. Based on this examination, the technician can adjust coaching for the next maneuver. Poorly performed or submaximal maneuvers may mimic disease patterns, leading to interpretive errors.

The start of test criteria requires an abrupt, sharp rise in flow with no hesitation. This is quantified by assessing the back extrapolated volume as illustrated in figure 5. At the onset of forced exhalation, inertial forces must be overcome; PEF is not achieved until approximately 150 msec after the exhalation maneuver begins. The extrapolated volume, calculated using the new “time zero,” must be less than 5% of the FVC or 0.150 L, whichever is greater. Most modern spirometers provide rapid computerized feedback to alert the technician when start-of-test criteria are not met. An inaccurate “start-of-test” with a large back extrapolated volume could overreport FEV_1 relative to FVC, resulting in an increased FEV_1/FVC ratio, possibly missing an obstructive pattern.



The back extrapolation method for determining time zero (the adjusted start time) and extrapolated volume are illustrated. The extrapolated volume must be less than 5% of the FVC or 0.150 L, whichever is greater.

Figure 5. The back extrapolated volume

The end-of-test criteria ensures that the patient has exhaled completely to residual volume (RV). The end-of-test criteria are met at an exhalation time of greater than 6 seconds (3 seconds for children < 10 years of age) or a plateau on the volume-time curve (defined as a change in volume < 25 mL for the last second of exhalation). Most currently available spirometers alert the technician if end-of-test criteria are not met.



An unacceptable spirogram due to coughing. Useful information may be obtained from spirograms with cough. If the cough occurs after the first second of exhalation, FEV_1 will be reliable.



An unacceptable spirogram due to transient occlusion of mouthpiece by tongue.

Figure 6. Examples of unacceptable spirogram.

Spirometry Repeatability (Between-Maneuver) Criteria

After three acceptable spirograms, apply the following criteria:

1. Are the two largest values of FVC within 0.15 L of each other?

2. Are the two largest values of FEV_1 within 0.15 L of each other?

If both criteria are met, conclude test session.

If criteria are not met, continue testing until criteria are met, patient is fatigued, or eight tests have been performed.

NORMAL LUNG FUNCTION

Results obtained from lung function tests have no meaning unless they are compared against reference values or predicted values. There are a number of reference values available that have been equated in slightly different ways, but for studies comparing different European communities, the equations from the European Community for Coal and Steel (ECCS) are often used. Reference values are derived from reference equations that contain data from population surveys. The population in the survey is ideally very large, and data is gathered about the subjects' height, weight, age, sex, ethnic origin, smoking habits, environment, working conditions and physical fitness. The current ECCS equations are linear in nature but in reality, lung function change is a nonlinear process. Reference values given can, therefore, be unrepresentative of the person being tested in some situations.

In adults, age, height, sex and race are the main determinants of the reference values for spirometric measurement.

- **Age.** Lung function generally increases with age up to ∼25 years, then declines with increasing age afterwards. Unfortunately, some lung function equipment will give patients aged <25 years larger predicted values than at age 25 years. To avoid majorly overestimating the predicted value for patients <25 years of age, the best course of action is input the subject's age as 16 years and then 25 years. If the predicted is larger at 16 years, then use the value for 25 years.
- **Sex.** Pre-pubescent males and females generally have the same lung function, but post-puberty, the growth of the thorax is greater in males, giving marked differences in lung volumes.
- **Height.** The taller the person, the bigger the lungs.
- **Weight**. Certain reference equations use weight to calculate reference values. Weight affects lung function in that increasing weight causes increasing lung function until obesity is reached, after which it has the opposite effect.
- **Ethnic origin**. This factor becomes more difficult to include as a multiethnic society develops. The BTS/ARTP guidelines suggest that for Japanese, Polynesian, Indian, Pakistani and African patients, and those of African descent, reference values multiplied by a factor of 0.90 should be used. This is due either to body shape (i.e. African people tend to have longer legs and shorter bodies than Caucasians) or lack of nutrition for those born in poorer countries. As many different ethnicities are now born in richer countries, nutrition is likely to be less of an issue and as a general rule, by the second generation after immigration, adjustment for race is not usually required. Flow measurements are not affected.
- **Smoking.** This can cause a more rapid decline in lung function compared with nonsmokers over time. It should not be adjusted for in predicted equations, since any reduction is abnormal.

SPIROMETRY INTERPRETATION

Spirometry results are compared to predicted values based on age, gender, height, and ethnicity.

It is accepted to divide the typical ventilation disorders into two types:

1. Restrictive disorders.
2. Obstructive disorders.

The elastic work of inspiratory muscles has been abnormally increasing during restrictive disorders. Patient's breathing is becoming superficial and frequent. Accessory inspiratory muscles are being involved to the respiratory cycle. Pulmonary fibrosis, silicosis (professional disease of miners), respiratory distress syndrome (surfactants deficiency) are the examples of restrictive disorders. Congenital and acquired chest skeleton deformations (kyphosis, scoliosis, funnel-shaped deformation) are referred to the special type of ventilation restrictive disorders. The chest skeleton elastic forces contributing to the chest dimension increase during inspiration are reduced in people with this type of disorders, what results in the overload of the inspiratory muscles.

In the case of obstructive disorders, the frictional work has been increasing what results in the involving of accessory inspiratory and expiratory muscles into breathing. The expiration is especially complicated. That's why the patient breathes deeply but relatively slowly, as far as such a ventilation regime is energy-cost profitable for him. The examples of obstructive disorders are: bronchial asthma, emphysema, chronic obstructive bronchitis.

A simple approach for interpreting spirometry is shown in Figure 7.



Severity classification

	FEV1 % predicted
Normal physiologic variant	>100
Mild	70–100
Moderate	60–69
Moderately severe	50–59
Severe	35–49
Very severe	<35

A simple algorithm for interpreting spirometry beginning with the FEV_1/FVC ratio is shown. A reduced FEV_1/FVC ratio, less than the lower limit of normal (LLN), is diagnostic of obstruction, and the severity of obstruction is determined by the FEV_1 percent predicted. Restriction is suggested if the FVC is reduced, although a reduced FVC is not specific for a restrictive pattern.

Figure 7. Interpretation algorithm

The first step is to assess the FEV_1/FVC ratio. Narrowing of either the large or the small airways will result in a larger reduction in FEV_1 relative to FVC, resulting in a reduced FEV_1/FVC ratio. The pathophysiologic processes in asthma and COPD primarily affect the mid to smaller airways and show a proportionally greater reduction in flow in the middle and later parts of exhalation. This produces the characteristic concave shape on the flow-volume curve.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines airway obstruction as a postbronchodilator FEV_1/FVC less than 70%. The GOLD guidelines advocate the use of the fixed ratio for FEV_1/FVC for reasons of simplicity and ease of remembrance, while acknowledging that the FEV_1/FVC decreases with age and may result in the overdiagnosis of COPD in the elderly. The process of aging results in a loss of elastic recoil; FEV_1 decreases more rapidly than FVC, resulting in a progressive reduction in the FEV_1/ FVC ratio with advancing age.

DEFINITION OF OBSTRUCTION
AND
CLASSIFICATION OF SEVERITY BY SPIROMETRY

ATS/ERS FEV_1/FVC <LLN		GOLD FEV_1/FVC <0.70	
FEV_1 % predicted		FEV_1 % predicted	
>70	Mild	Stage I: Mild	≥80
60–69	Moderate	Stage II: Moderate	<80
50–59	Moderately severe		
35–49	Severe	Stage III: Severe	<50
<35	Very severe	Stage IV: Very severe	<30

The American Thoracic Society and European Respiratory Society (ATS/ERS) defines obstruction as an FEV_1/FVC ratio below the lower limit of normal (LLN) defined as below the 5th percentile of the predicted value. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines obstruction as a FEV_1/FVC ratio less than 0.70. Both grade the severity of obstruction based on the FEV_1 percent predicted.

Figure 8. Criteria for defining and classifying airflow obstruction.



Examples of flow-volume curves for healthy subjects aged 20, 50, and 80 years. The FEV_1/FVC ratio decreases with age, primarily due to a loss of elastic recoil. The changes in flow with ageing are most evident at lower lung volumes.

Figure 9. Examples of spirogram at different age.

Another controversy arises in classifying those whose FEV$_1$/FVC ratio is reduced but the FEV$_1$ is in the normal range. Patients with this pattern have been identified as obstructed or a "normal physiologic variant" when FEV$_1$ was greater than 100% of predicted. Accurate interpretation of subjects with a reduced FEV$_1$/FVC ratio and a preserved FEV$_1$ requires clinical information, because it depends on the prior probability of obstructive disease. In healthy individuals, this pattern may represent unequal growth of the airways relative to the lung parenchyma, but in people with respiratory symptoms or exposures, it probably represents airway obstruction.

A restrictive ventilatory defect is defined as a total lung capacity (TLC) below the 5th percentile of the predicted value. Because spirometry is much more readily available, technically easier, and less costly to perform than measurements of lung volumes (plethysmography, nitrogen washout, or inert gas techniques), FVC is often used as a surrogate for TLC to diagnose a restrictive abnormality. Spirometry-based algorithms can exclude a restrictive process with greater than 95% accuracy if the FVC is normal. However, a low FVC cannot reliably diagnose restriction. A reduced FVC has a positive predictive value of only approximately 50% for confirming a restrictive process with only modest improvements in accuracy if reserved for patients with a normal FEV$_1$/FVC ratio. Spirometry is helpful in excluding but not predicting a restrictive defect. VC will be reduced despite a normal TLC if inspiratory or expiratory efforts are submaximal and if there is air trapping associated with small airway closure or non-communicating bullae.

It is not uncommon to identify patients with a reduced FEV$_1$ and FVC with a normal FEV$_1$/FVC ratio and normal TLC. This has been referred to as a "nonspecific pattern" and was found in approximately 10% of patients. The majority of patients with this pattern had either airway hyperresponsiveness or abnormalities that restrict the normal expansion of the lung or thorax such as obesity.

A mixed or combined ventilatory defect is present when both the FEV$_1$/FVC ratio and the TLC are below the 5th percentiles of their predicted values. A reduced FVC associated with a reduced FEV$_1$/FVC ratio is most likely due to hyperinflation, although a concomitant restrictive process cannot be ruled out without measurement of TLC by plethysmography.

Though the FEV1/FVC ratio is the spirometric standard for diagnosing obstruction, the FEV$_1$/FEV$_6$ ratio is an acceptable surrogate. The FEV$_6$ maneuver, which allows cessation of exhalation after 6 seconds, has several advantages over the standard FVC maneuver. It is less physically demanding for the patient. It simplifies spirometric testing for the technician, shortens testing time, and has superior reproducibility. The FEV_1/FEV_6 ratio performs well in categorizing patients with obstruction with a sensitivity and specificity greater than 90% compared with the FEV1/FVC ratio.

BRONCHODILATOR TESTING

Bronchodilator administration in the pulmonary function laboratory is commonly performed to determine acute reversibility of airflow limitation. The ATS/ERS Task Force recommends the administration of four separate puffs at 30-second intervals of the short acting b2-agonist albuterol (total of 400 mcg) using a spacer device. For pre- and postbronchodilator spirometry studies, a minimum of three acceptable and repeatable tests should be obtained at baseline and 15 minutes after bronchodilator administration. If the short-acting anticholinergic drug ipratropium bromide is used, testing should be repeated 30 minutes after administration. The combination of albuterol and ipratropium produces a greater response than either medication alone. The ordering physician's purpose is paramount in determining the conditions of testing: If the aim of the study is to determine whether there is any evidence of reversible airflow obstruction, the patient should not take short-acting bronchodilators for 4 to 6 hours prior to testing and long-acting bronchodilators 12 to 24 hours before testing. However, if the goal is to determine whether lung function can be improved above that achieved with baseline treatment, medications should be taken as prescribed.

The ATS/ERS Task Force defines a positive bronchodilator response as an increase in FEV_1 and/or FVC greater than or equal to 12% and 200 mL of the baseline value. The clinical utility of acute bronchodilator testing is not well defined. The National Asthma Education and Prevention Program Expert Panel Report recommends measuring pre- and postbronchodilator pulmonary function in asthmatics. The GOLD guidelines recommend the use of postbronchodilator spirometry for diagnosis and staging of COPD. It is not clear how an acute response to bronchodilator in the laboratory influences the management of patients with asthma or COPD. One reported benefit of bronchodilator testing is to distinguish between asthma and COPD. Reversible airflow obstruction is the hallmark for asthma and irreversible obstruction is often a characteristic of COPD. However, it is not uncommon for patients with COPD to respond acutely to bronchodilator; some studies report more than 50% of subjects met criteria for reversibility. There is significant overlap between response to bronchodilator for patients with asthma and those with COPD, and it cannot reliably differentiate between asthma and COPD. There are some quantitative and qualitative patterns more commonly associated with one than the other. In general, asthmatics have a larger absolute increase in FEV1 than patients with COPD. In COPD patients who respond to bronchodilator, there often is an increase in FVC, whereas individuals with asthma more often respond with an increase in FEV1. Asthma is a disease characterized by variability in bronchial responsiveness and in bronchodilator reversibility.



Patients with airflow obstruction may improve following the administration of bronchodilator in two ways: FEV_1 and/or FVC may improve by 12% and 200 mL (**A**), or there may be a reduction in hyperinflation manifest by an increase in inspiratory capacity (**B**). A reduction in hyperinflation is associated with clinical improvement.

Figure 10. Example of bronchodilator testing

SPIROMETRY IN UPPER AIRWAY OBSTRUCTION

The upper airway extends from the nose or mouth to the main carina of the trachea. The upper airway is further subdivided into the extrathoracic and intrathoracic components. The extrathoracic airway includes the nose, mouth, pharynx, larynx, and the 2 to 4 cm of the trachea cephalad to the thoracic inlet. The intrathoracic component comprises the 6 to 9 cm of trachea extending from the thoracic inlet caudal to the main carina. Spirometry is very useful in identifying upper airway obstruction (UAO). UAO may present in a similar manner to the more common causes of airway obstruction such as asthma and COPD. Differentiating UAO from these more common causes of airway obstruction is important because treatment is very different and confirmatory diagnostic tests are required.

Three patterns of UAO can be identified by examining the inspiratory and expiratory components of the flow volume tracing. The UAO pattern is determined by the location of the obstruction (intrathoracic or extrathoracic) and whether the obstruction is fixed or variable. Reviewing the physiologic principles that govern air movement into and out of the airways can identify the pattern of obstruction observed with the flow-volume curve. Transmural pressure gradients develop across the upper airway wall with inhalation and exhalation. Whether the transmural pressure is positive or negative depends on the phase of respiration (inhalation or exhalation) and on the location of the obstruction. Under normal circumstances, the integrity of the airway wall prevents crimping or expansion, preserving airflow. With variable extrathoracic obstruction, as depicted in Figure 11, transmural pressure is negative with inhalation, resulting in crimping of the airway at the site of the lesion, reducing airflow and flattening the inspiratory limb of the flow-volume tracing.



Figure 11. Changes in upper airway diameter with variable extrathoracic obstruction.

With exhalation, transmural pressure is positive, decreasing the degree of obstruction and improving flow. Patient effort is especially important when using the flow-volume curve to diagnose UAO. The most common cause of inspiratory limb flattening is submaximal inspiratory effort. Causes of extrathoracic UAO include tracheomalacia; vocal cord abnormalities (paralysis, edema, neoplasms, vocal cord dysfunction); thyroid tumors; laryngeal edema (angioedema, post-extubation, burns); epiglottitis, tonsillar, and retropharyngeal abscesses; and foreign bodies.

Variable intrathoracic obstruction is shown in Figure 12. Transmural pressure is negative with exhalation as pleural pressure exceeds intratracheal pressure, crimping the airway downstream of the site of the lesion, reducing airflow and flattening the expiratory limb of the flow-volume curve. With inhalation, tracheal pressureexceeds surrounding pleural pressure, no compression downstream occurs, resulting in greater inspiratory flow. Causes of variable intrathoracic obstruction include tracheomalacia, tracheal tumors, tracheal inflammatory processes (Wegener's granulomatosis, tracheitis), and mediastinal adenopathy.



Figure 12. Changes in upper airway diameter with variable intrathoracic obstruction.

Similar to variable extrathoracic obstruction discussed previously, most causes of variable intrathoracic obstruction result in reductions of both expiratory and inspiratory flows with more pronounced reductions in expiratory flows. The exception is intrathoracic tracheomalacia, which exhibits only expiratory limb flattening with a preserved inspiratory limb. Fixed lesions of the upper airway are firm and relatively resistant to the effects of transmural pressure changes. They do not change significantly with the phase of respiration and both the inspiratory and the expiratory limbs of the flow-volume curve are similarly flattened (as illustrated in Fig. 13). The most common cause of fixed UAO is subglottic stenosis from prior intubation or tracheostomy. Other causes include benign and malignant tumors anywhere in the upper airway, large thyroid goiters, and large foreign bodies.62 Tracheomalacia located at the thoracic inlet will also result in near-equal reduction in both inspiratory and expiratory flows.



With fixed upper airway obstruction, there is flattening of both the inspiratory and the expiratory limbs of the flow-volume curve. $FEF_{50\%}$ is approximately equal to $FIF_{50\%}$.

Figure 13. Flattening of both limbs of the flow-volume curve.

The ratio of forced expiratory flow at 50% of lung volume to forced inspiratory flow at 50% of lung volume (FEF50/FIF50) is a simple test for determining the type of UAO. The following ratios for FEF50%/FIF50%: normal individuals of 1.0 or greater; fixed upper airway obstruction 0.9; variable extrathoracic UAO 2.2; and variable intrathoracic obstruction 0.3. The diagnosis of UAO is more difficult when there is concomitant “lower” airway obstruction associated with asthma or COPD. Four variables derived from the FVC maneuver to be useful in distinguishing UAO from normal subjects and patients with COPD. These included: FIF50% of 100 L/min or less; FEF50%/FIF50% of 1.0 or greater; FEV1/PEF of 10 mL/L/min or greater; and FEV1/FEV0.5 of 1.5 or greater.

DIFFUSING CAPACITY PHYSIOLOGY

The diffusing capacity for carbon monoxide (DL_{CO}) is a common and clinically useful test that provides a quantitative measure of gas transfer in the lungs. DL_{CO}, along with spirometry, is a core PFT used to evaluate and manage patients with respiratory diseases. Diffusing capacity is often abnormal in patients with interstitial lung disease, pulmonary vascular disease, and COPD. Because DL_{CO} is a measure of the transfer of gas from the airways to the reaction with hemoglobin in the pulmonary capillaries, DL_{CO} has been called a “window on the pulmonary microcirculation. Diffusing capacity is influenced by processes in addition to diffusion and is usually obtained at rest when it is submaximal so it is not a true capacity measurement. Measuring DL_{CO} provides information on the transfer of gas from the airways to hemoglobin. This is depicted in Figure 14.



The transfer of carbon monoxide and oxygen molecules across the alveolar-capillary membrane, through plasma, across the red blood cell membrane and the reaction with hemoglobin is represented.

Figure 14. Transfer of carbon monoxide molecules across the membrane.

The gas essential to cellular metabolism is O_2 but CO is used in the test. Why is the diffusion of CO measured rather than the diffusion of O_2? Both CO and O_2 readily diffuse across the alveolar capillary membrane and bind tightly with hemoglobin. However, CO has a binding affinity for hemoglobin 200 to 250 times greater than that of O_2. Because of the high affinity combined with the abundance of CO binding sites on the hemoglobin molecule, the pulmonary capillary CO tension remains near zero when low concentrations of CO are inhaled. The CO uptake is therefore diffusion limited. In contrast, the pulmonary capillary O_2 tension or partial pressure rises along the length of the capillary, creating appreciable back tension (Fig.15).



This figure illustrates why oxygen (O_2) uptake is perfusion limited under most clinical circumstances, because the capillary partial pressure of O_2 rapidly increases along the length of the pulmonary capillary, while the capillary partial pressure of carbon monoxide, at low concentrations, remains near zero and its uptake is limited by diffusion.

Figure 15. Uptake of O_2 and CO.

Oxygen is perfusion- limited in normoxic conditions and perfusion and diffusion-limited in hypoxic conditions. Despite the fact that O_2 is the primary gas of interest, technical factors preclude measurement of DLO_2. At the present time, CO is the best gas to measure the diffusion properties of the lung.

Fick's law describes the diffusion of a gas through tissue. The amount of gas transferred across a membrane is directly proportional to the tissue surface area, diffusion constant, and the difference in gas partial pressure and is inversely proportional to the tissue thickness. The diffusion constant is proportional to the solubility of a gas and is inversely proportional to the square root of the molecular weight of the gas. The single-breath technique is the most common method for measuring DL_{CO}. Its advantages are that it has been standardized by the ATS/ERS Task Force, there are well-defined reference values for healthy subjects, and the majority of clinical studies have used this method. Diffusing capacity can be measured using other techniques including the steady state, rebreathing, intrabreath, and multiple inert gas methods. These are more technically demanding.

TABLE 24-6. Degree of Severity of Decrease in DL_{CO}

Degree of Severity	DL_{CO} % Predicted
Mild	>60% and <LLN
Moderate	40%–60%
Severe	<40%

DL_{CO}, diffusing capacity for carbon dioxide; LLN, lower limits of normal.
Modified from Pellegrino R, Viegi G, Brusasco V, et al: Interpretative strategies for lung function tests. Eur Respir J 26:948–968, 2005.

Figure 16. Diffusing capacity interpretation.

Diffusing capacity interpretation is most clinically useful when it is performed in conjunction with measurements of spirometry and lung volumes. A low DL_{CO} with normal spirometry suggests the presence of pulmonary vascular disease, early interstitial lung disease, emphysema associated with a restrictive lung process, anemia (reduced hemoglobin), or elevated carboxyhemoglobin level. Pulmonary vascular diseases such as idiopathic pulmonary artery hypertension, pulmonary embolism, chronic thromboembolic pulmonary hypertension, and pulmonary vasculitis should be considered in a patient with a significant reduction in DL_{CO} and normal spirometry and lung volumes. Early interstitial lung disease can cause mild to moderate reductions in DL_{CO} before the development of abnormal spirometry and lung volumes. A reduced DL_{CO} is often an early manifestation of interstitial lung disease, and a low DL_{CO} in a patient with dyspnea should lead to further evaluation such as a high-resolution CT scan of the chest. Emphysema with a concomitant restrictive process such as idiopathic pulmonary fibrosis, amiodarone-induced interstitial lung disease, and hypersensitivity pneumonitis has been associated with a reduced DL_{CO} and normal spirometry and lung volumes.

Most disease processes reduce DL_{CO}. A few disorders are associated with an elevated DL_{CO}, defined as a DL_{CO} greater than 140% of predicted value. The most common cause of an elevated DL_{CO} is obesity, probably due to increased pulmonary capillary blood volume. Other disease processes associated with an elevated DL_{CO} include pulmonary hemorrhage syndromes (e.g., Wegener's granulomatosis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis), polycythemia, left-to-right intracardiac shunts, and asthma.

LUNG VOLUMES

Lung volumes are useful for detecting and physiologically characterizing the nature and severity of lung diseases. While spirometry measures inhaled and exhaled lung volumes, the term "lung volumes" is generally reserved for the measurements TLC, functional residual capacity (FRC), and RV. A reduced TLC defines a restrictive pattern. Four techniques are commonly used to measure lung volumes: body plethysmography, nitrogen washout, inert gas dilution, and radiographic imaging methods.

Definitions of "Volumes" and "Capacities"

TLC can be divided into several subdivisions grouped as "volumes" and "capacities." Two or more "volumes" make up a "capacity."

The four basic volumes are:

- tidal volume
- inspiratory reserve volume
- expiratory reserve volume
- residual volume

The four basic capacities are:

- TLC
- VC
- inspiratory capacity
- FRC

Figure 17 illustrates the most commonly measured lung volumes and capacities.



The four basic lung volumes are: inspiratory reserve volume (IRV), tidal volume (VT), expiratory reserve volume (ERV), and residual volume (RV). The four basic lung capacities are: total lung capacity (TLC), forced vital capacity (FVC), inspiratory capacity (IC), and functional residual capacity (FRC).

Figure 17. Lung volumes.

TLC (Total lung capacity) is the amount of air in the lungs at the end of a maximal inhalation. It is attained when the recoil forces of the lung and chest wall counterbalance the maximal inspiratory muscle force.

RV (Residual volume**)** is the amount of air in the lungs at the end of a maximal exhalation. It is determined by the balance of the forces tending to reduce lung volume (maximal expiratory muscle force and inward lung recoil) against the outward recoil of the chest wall.

VC (Vital capacity) is the volume of air that can be exhaled after a maximal inhalation. TLC is, therefore, the sum of RV and VC.

Inspiratory capacity is the amount of air that can be inhaled from the end of a tidal exhalation.

FRC (Functional residual capacity) is the volume of air in the lungs at the end of a relaxed exhalation and is the critical measurement obtained with lung volume testing.

ERV (Expiratory reserve volume) is the volume of air that can be exhaled from the end of a tidal exhalation.

IRV (Inspiratory reserve volume) is the volume of air that can be inhaled from the end of a tidal inspiration.

Lung volumes are indicated to confirm a restrictive pattern in a patient with a reduced VC. A reduced VC suggests restriction but has a poor positive predictive value for confirming a restrictive process. That is, a normal VC excludes a restrictive process but a reduced VC accurately predicts restriction in only approximately 50% of patients.

Four basic lung volume patterns can be identified based on pathophysiology: **normal**, **hyperinflation**, **restriction**, and associated with **neuromuscular disease** (Fig. 18). Measurement of lung volumes is necessary to definitively characterize these patterns. In young healthy adults, RV constitutes about 25% of TLC and FRC about 40% of TLC. In hyperinflation, often present in patients with COPD, decreased elastic recoil results in an increased TLC, RV, and FRC. Restrictive processes are characterized by reduced lung or chest wall compliance and appear as proportional reductions in TLC, RV, and FRC. Neuromuscular diseases also cause a restrictive pattern. The characteristic pattern of neuromuscular disease is a reduced TLC associated with an increased RV.



Four basic lung volume patterns are illustrated: normal, hyperinflation, restriction, and neuromuscular disease.

Figure 18. Types of lung volumes patterns.

Clinical Utility of Lung Volume Testing

While lung volume measurements are necessary to confirm a restrictive pattern and to characterize pathophysiologic processes, their role in clinical management is unclear. Lung volume measurements are often helpful in the evaluation of patients with a reduced VC. A restrictive pattern caused by decreased lung compliance is seen in patients with interstitial lung disease and lung volume measurements are suggested in the evaluation of patients with interstitial lung disease. A restrictive pattern is also seen in patients with decreased chest wall compliance. Decreased chest wall compliance is present in many different disease processes including kyphoscoliosis, ankylosing spondylitis, pleural effusions, fibrothorax, thoracoplasty, and morbid obesity. Neuromuscular diseases also result in a restrictive pattern. Expiratory muscle weakness causes an increase in RV, while inspiratory muscle weakness limits inspiration to TLC.

Measurement of lung volumes can be clinically useful in patients with COPD. A reduced VC is common in patients with COPD. The causes of this reduction include submaximal effort or air trapping associated with small airway closure or noncommunicating bullae. Measuring TLC with plethysmography in patients with COPD and a reduced VC can exclude a concomitant restrictive process. Moderate to severe airway obstruction is associated with air trapping, which leads to hyperinflation. Hyperinflation causes dyspnea at rest that worsens with even mild exertion. Air trapping and overinflation of the lungs reduces inspiratory capacity and is a primary hallmark of hyperinflation. In patients with COPD, inspiratory capacity predicts symptoms, quality of life, and exercise capacity better than spirometry. Hyperinflation, manifested by a reduced IC/TLC ratio is an independent risk factor for mortality in patients with COPD. The IC/TLC ratio is a better predictor of mortality than FEV1 and it predicts mortality independent of the multi-dimensional grading system that includes the body mass index, measure of airflow obstruction, dyspnea score and exercise capacity commonly referred to as the BODE index.

TECHNIQUES FOR MEASURING LUNG VOLUMES

All techniques used to measure lung volumes have technical limitations. The laboratory-based tests require a two-step process. FRC is measured with body plethysmography, nitrogen washout, or inert gas dilution techniques. The inspiratory capacity obtained from spirometry is added to FRC to determine TLC. In healthy subjects and patients with interstitial lung disease, all three methods provide similar results. However, in patients with obstructive lung disease, nitrogen washout and gas dilution methods will significantly underestimate the lung volume obtained with body plethysmography. In patients with severe obstructive lung disease, the difference in TLC can exceed 3 L.

Body plethysmography is considered the “gold standard” technique for measuring lung volumes. The test can be performed quickly, and repeated measurements can be obtained in a single session. It is, however, technically demanding and requires expensive, complex, and space-consuming instruments, and for these reasons, it is usually not performed in physician’s offices. Plethysmography measures compressible gas volume in the chest based on Boyle's law (i.e., at a constant temperature, the product of gas volume and pressure is a constant). The patient sits in a sealed box connected to a mouthpiece and gently pants against a closed shutter at FRC. The panting frequency should not exceed 1 pant/sec. If the panting is too rapid, mouth pressure and alveolar pressure will not equilibrate and TLC will be overestimated. The thoracic gas volume is calculated from the slope of the pressure-volume curve obtained by the compression and decompression of the gas in the chest during the panting maneuver. A total of three to five loops should be recorded with similar slopes. The interpreting physician must examine the slopes that are determined automatically by computerized systems. The criteria for an adequate test are at least three plethysmographic FRC values that agree within 5%; the mean value is reported.

Figure 19. Plethysmography

Inert gas dilution techniques are another common technique used to measure lung volumes. These tests use the mass balance approach to calculate lung volumes. The patient inhales a known concentration and volume of an inert gas, usually helium, methane, or neon, and the gas is allowed to mix. Because the initial volume and concentration of the inert gas are known, determining the exhaled concentration of the inert gas allows the calculation of the volume present in the patient's lungs at the moment tracer gas breathing began. The major limitation of this method is that it measures only the gas volume in the lungs that directly communicates with the mouth. Unlike body plethysmography, which measures total thoracic gas volume, inert gas dilution methods can underestimate TLC in obstructed patients with "air trapping."

A third method for determining lung volumes is nitrogen washout. Nitrogen washout techniques also use a mass balance approach to estimate TLC and, as with the inert gas dilution techniques, the test measures only the lung gas volume that communicates directly with the mouth. Trapped gas is not measured and TLC is underestimated in patients with obstructive lung disease. Nitrogen washout lung volumes can be obtained using either a single-breath or a multiple-breath technique. The single-breath technique requires the inhalation of 100% O_2 with measurement of the nitrogen concentration in the exhaled gas. The single-breath technique allows the determination of closing volume. The single-breath technique significantly underestimates TLC compared with the multiple-breath technique. Most laboratories that use nitrogen washout rely on the multiple-breath technique to determine lung volumes. In the multiple-breath nitrogen washout method, the patient breathes 100% O_2 at FRC with continuous collection and monitoring of the exhaled nitrogen gas. FRC is calculated based on the assumption that the mass of displaced nitrogen is equal to the mass of nitrogen in the lungs at the beginning of the test and that the initial concentration of nitrogen in the lungs was 80%. The multiple-breath nitrogen washout test requires minimal patient effort and coordination. It is very sensitive to leaks in the system. A prolonged waiting period is required before the test can be repeated in patients with airflow obstruction, making it difficult to perform more than one measurement in a test session.

BRONCHIAL PROVOCATION TESTS

Bronchial provocation (bronchoprovocation) tests are performed to assess bronchial hyperresponsiveness (BHR). They involve the administration of a stimulus that causes airway narrowing in susceptible patients. Bronchoprovocation tests are primarily used to confirm a diagnosis of asthma but are most clinically useful when the diagnosis is not clear-cut. Asthma is a chronic disorder of the airways characterized by variable and recurring symptoms, airflow obstruction, BHR, and underlying inflammation. The diagnosis of asthma is most often made with a history of intermittent respiratory symptoms in combination with variable airflow obstruction. While BHR is a key feature of asthma, bronchoprovocation tests are not often necessary to establish the diagnosis.

Indications for Bronchial Provocation Testing :

Indications for bronchoprovocation include:

1. Establishing a diagnosis of asthma when atypical features are present: Asthma symptoms with normal spirometry, a presumptive diagnosis of asthma that does not improve with asthma therapy, or nonspecific asthma symptoms such as persistent cough are common reasons to obtain the test.

2. Evaluating the possibility of occupational asthma: Bronchoprovocation testing is generally a sensitive but not specific test for diagnosing occupational asthma.

3. Excluding a diagnosis of asthma in patients for whom an erroneous diagnosis has significant social impact (military recruits, divers, firefighters, and

other high-risk occupations).

4. Monitoring asthma therapy: Symptoms and lung function may normalize despite ongoing airway inflammation; BHR correlates well with airway inflammation, and adjusting therapy based on BHR may improve outcomes.

5. Identifying specific asthma triggers. It is rarely necessary to perform specific bronchial challenge testing with the suspected offending agent, although it may be performed for research or legal purposes.

6. Objectively assessing asthma severity.

Contraindications for Bronchial Provocation Testing:

ABSOLUTE

- Severe airflow limitation (FEV1 < 50% predicted or <1.0 L)
- Acute coronary syndrome or stroke within 3 months
- Severe hypertension (systolic BP > 200 mm Hg or diastolic BP > 100 mm Hg)
- Cerebral or aortic aneurysm

RELATIVE

- Moderate airflow limitation (FEV1 < 60% predicted or <1.5 L)
- Inability to perform acceptable and repeatable spirometry
- Pregnancy*
- Nursing mothers*
- Current use of cholinesterase inhibitor medication for myasthenia gravis*

- Significant hypoxemia (PaO2 < 60)
- Recent upper or lower respiratory tract infection (within 6 wk)
- Failure to withhold medication that may affect test results
- Vigorous exercise on day of test

*Relative contraindications for methacholine administration.

Categories of Bronchoprovocation Tests

There are three broad categories of bronchoprovocation tests. Bronchial hyperreactivity can be elicited using

- specific airway irritants,
- "direct" stimuli using nonspecific pharmacologic agents (methacholine and histamine)
- "indirect" stimuli (exercise, eucapnic voluntary hyperventilation, cold air hyperventilation, hypertonic saline, mannitol, and adenosine monophosphate [AMP]).

The direct airway challenges cause airway narrowing via a direct effect on airway smooth muscle whereas indirect airway challenges cause airflow obstruction by acting on airway inflammatory and neuronal cells, which release mediators or cytokines that provoke bronchoconstriction.

Specific inhalation challenge tests with substances found in the workplace are considered the gold standard for confirming or diagnosing occupational asthma. However, a negative test may not definitively exclude the diagnosis of occupational asthma if the wrong agent or too low a concentration is used. Moreover, these tests require specialized equipment and have the potential to trigger severe life-threatening asthmatic reactions. They should be performed only at specialized centers and are not widely available.

MCQS WITH EXPLANATION

1. A 56-year-old man had seizure-like activity and then lost consciousness within minutes after surfacing from a recreational 55-foot dive with some friends. His friends laid him on his side and called emergency services. When the emergency response team arrived, the patient had altered mental status. His blood pressure was 92/54 mm Hg, and his heart rate was 115 beats per minute. The patient's medical history is

significant for paroxysmal atrial fibrillation with failed catheter ablation. Current medications are metoprolol, a daily low-dose aspirin, and a daily multivitamin. On physical examination, his skin appears mottled, and his breath sounds are shallow. Which of the following is the next best step in managing this patient?

A. Give a loading dose of phenytoin followed by 12-hour infusion.

B. Insert 2 large-bore IVs and start high-volume fluid resuscitation.

C. Secure the patient's airway, administer 100% oxygen, and transport the patient rapidly for hyperbaric recompression.

D. Obtain a non-contrast computed tomography scan of the head and administer tissue plasminogen activator.

E. Obtain an electrocardiogram, and administer bolus amiodarone.

EXPLANATION:

Correct answer C: The patient has cerebral air embolism (also called arterial gas embolism or AGE), the most serious potential complication of barotrauma in divers. AGE can occur when venous air bubbles enter the pulmonary vasculature after too rapid of an ascent or from breath-holding during ascent (see image).



Image: Pathophysiology of barotrauma and gas emboli. By: Lecturio

If a diver has a patent foramen ovale, the gas bubbles can enter arterial circulation and cause symptoms from cerebral emboli. Gas emboli can occlude circulation anywhere in the body and cause end-organ damage in the brain, heart, kidneys, muscles, etc. Therefore, the patient must receive treatment to resolve the gas bubbles immediately to avoid further complications, including possible myocardial ischemia.

The first-line treatment for decompression sickness with evidence of gas emboli is administration of 100% oxygen and rapid transport for recompression in a hyperbaric chamber. First-responders should ensure the airway is secure and intubate the patient if needed or administer the oxygen via a close-fitting mask.

Option A: Phenytoin would be a possible treatment for seizures; however, this patient's seizure-like activity is likely due to cerebral arterial gas embolism, which is the issue that needs to be treated.

Option B: Large-bore IVs are necessary for volume repletion and rapid medication administration in emergency resuscitation. High-volume fluid resuscitation is not needed, although it would be prudent to start an IV line. However, with this patient's arterial gas embolism and decompression sickness, the most immediate treatment to prevent further complications is 100% oxygen and hyperbaric therapy.

Option D: Tissue plasminogen activator would be appropriate for loss of consciousness and altered mental status due to brain ischemia secondary to thromboembolism. Although this patient does have signs of brain ischemia and has risk factors for thromboembolic stroke, specifically atrial fibrillation, given the abrupt onset of symptoms after surfacing from diving, a cerebral gas embolism is more likely.

Option E: Amiodarone would be a possible treatment for paroxysmal atrial fibrillation. Although the patient experienced dizziness, fatigue, and weakness, which can be signs of symptomatic atrial fibrillation, those symptoms also are consistent with decompression sickness. The patient is tachycardic but not clearly in atrial fibrillation at this time, and the abrupt onset of symptoms plus association with resurfacing from a dive make decompression sickness a more likely cause. It is prudent to obtain an electrocardiogram but not to administer bolus amiodarone.

Learning objective: Cerebral arterial gas embolization ("the bends") is a life-threatening condition caused by the formation of gas bubbles in blood vessels when a patient surfaces from a dive too rapidly. The bubbles prevent proper blood flow and can result in brain ischemia or other end-organ damage. Typical presenting symptoms include loss of consciousness, skeletal pain, and breathing problems. Management includes stabilizing the patient's airway, administering 100% oxygen, and rapid transport for recompression in a hyperbaric chamber.

2. A 15-year-old boy and his mother were referred to a pulmonology clinic. She is concerned that her son has been having breathing difficulty for the past few months, aggravated by exercise. The family is especially concerned because the patient's older brother has cystic fibrosis. The past medical history is noncontributory. Today, his blood pressure is 119/80 mm Hg, pulse is 90/min, respirations are 17/min, and temperature is 37.0°C (98.6°F). On physical exam, he appears well-developed and well-nourished. The heart has a regular rate and rhythm, and the lungs are clear to auscultation bilaterally. During the exam, he is brought into a special room to test his breathing. A clamp is placed on his nose and he is asked to take in as much air as he can, and then forcefully expire all the air into a spirometer. The volume of expired air represents which of the following?

A. Expiratory reserve volume

B. Functional residual capacity

C. Tidal volume

D. Total lung capacity

E. Vital capacity

EXPLANATION:

Correct answer E: The vital capacity is the maximum volume of air that can be forcefully expired after the deepest possible inspiration. As the graph shows, vital capacity is the sum of the inspiratory reserve volume, tidal volume, and expiratory reserve volume.



Image: Lung volumes and capacities. By Kapwatt, License: GNU Free Documentation License

When this patient inspires the maximum amount of air physiologically possible, the volume of air inspired is the inspiratory capacity (IC). Upon exhalation, this inspiratory capacity is passively expelled, and further forceful expiration pushes out the remaining air called the expiratory reserve volume (ERV). The residual volume (RV) cannot be measured by spirometry as an individual can't move that air into the spirometer. Residual volume is the volume of air left in the lungs after maximal, forceful expiration. The following table lists the average normal lung volumes and capacities in healthy adults:

Volume/capacity	**Average value (mL)**	
	Men	**Women**
Inspiratory reserve volume	3,100	1,900

Tidal volume	500	500
Expiratory reserve volume	1,200	700
Residual volume	1,200	1,100
Vital capacity	4,800	3,100
Inspiratory capacity	3,500	2,400
Functional residual capacity	2,300	1,800
Total lung capacity	5,800	4,200

Note that these values can vary greatly from individual to individual.

Option A: The expiratory reserve volume is the volume of air that can be forcefully expired at the end of a normal expiration.

Option B: The functional residual capacity is the air volume remaining in the lungs at the end of normal expiration. As the graph shows, it is the sum of the residual volume and the expiratory reserve volume.

Option C: The tidal volume is the volume of air that is inspired and expired in each breath while at rest. In healthy individuals, the normal tidal volume is about 500 mL or 7 mL/kg body weight.

Option D: Total lung capacity is the maximum volume of air the lungs can hold with maximum inspiration. It is a sum of the vital capacity and residual volume. It cannot be obtained via spirometry because residual volume cannot be measured.

Learning objective: Spirometry tests pulmonary function by assessing the flow of air into and out of the lungs. It cannot be used to determine residual volume.

3. A 75-year-old man presents to his physician with difficulty breathing for the last two months. He has had a dry cough but denies any fever or chest pain. His past medical

history is significant for hypertension for which he takes chlorothiazide. He has worked in the construction industry, applying insulation to roofs, for over 20 years. He denies smoking, drinking, and illicit drug use. His pulse is 74/min, respiratory rate is 14/min, blood pressure is 130/76 mm Hg, and temperature is 36.8°C (98.2°F). Physical examination reveals end-inspiratory crackles at both lung bases. No other examination findings are significant. The lung inflation curve is obtained for him and is shown in the image. Which of the following most likely accounts for this man's symptoms?



Image by Lecturio

A. Normal aging

B. Alpha-1 antitrypsin deficiency

C. Asthma

D. Emphysema

E. Idiopathic pulmonary hypertension

F. Pulmonary fibrosis

EXPLANATION:

Correct answer F: Pulmonary fibrosis. Lung compliance is the ability of the lung to stretch and expand and is defined as the change in volume divided by the change in pressure. Plotting lung volume versus transpulmonary pressure produces a curve whose slope represents lung compliance (see image).

This man's lung inflation curve shows significantly reduced compliance (lower lung volumes than the normal curve line at the same transpulmonary pressures), which is typical of restrictive pulmonary diseases like pulmonary fibrosis. Shipbuilders, miners, insulators, and plumbers are at increased risk for this pathology due to asbestos exposure in the workplace. The shortness of breath and the finding of end-inspiratory crackles are typical symptoms of pulmonary fibrosis.

The following graph shows the changes in pulmonary compliance for various conditions relative to normal healthy patients:



Image: Lung compliance for various pathologies relative to normal, healthy individuals. By Lecturio

Option A: In normal healthy individuals, lung compliance tends to increase slightly with age due to loss of elasticity, and chest wall compliance decreases due to stiffening of the bony structures of the thoracic cage, resulting in minimal change to the overall respiratory system's compliance.

Option B: Alpha-1 antitrypsin deficiency leads to emphysema and liver cirrhosis. Compliance is increased in emphysema.

Option C: Asthma produces a negligible increase in pulmonary compliance. The main impairment in asthma is decreased airflow through the bronchioles, and pulmonary compliance is preserved.

Option D: Pulmonary compliance is significantly increased in emphysema and increases further as the disease progresses. Alveolar wall destruction underlies the pathology of emphysema and this results in loss of elastic tissue (and therefore, the elastic recoil of the lung).

Option E: Idiopathic pulmonary hypertension is a rare disorder characterized by elevated pulmonary artery pressures without any identifiable cause. It has no effect on pulmonary compliance.

Learning objective: Pulmonary compliance is a measure of the ability of the lungs to expand. It is defined as

Compliance = Δ lung volume / Δ transpulmonary pressure.

Compliance is increased when the lungs can expand more easily, as in emphysema and normal aging, while it is decreased in restrictive lung diseases such as pulmonary fibrosis.

4. A 42-year-old woman presents to the clinic for worsening fatigue and difficulty breathing for the last 6 months. Previously, she could routinely walk 3 miles after dinner, but now she becomes short of breath after walking only 2 blocks. She also reports being tired soon after starting any physical activity. On review of systems, she has had intermittent fevers, occasional night sweats, and weight loss of 5 kg (11 lb) over the last 6 months. Her past surgical history is significant for 2 cesarean deliveries in her 20s and an appendectomy in her teens. She currently takes no medications and denies smoking and recreational drug use. She drinks half a glass of wine with her evening meal. Vital signs are temperature 36.7°C (98.0°F), heart rate 88/min, respiratory rate 14/min, and blood pressure 110/89 mm Hg. Physical examination is normal. A chest X-ray shows bilateral hilar lymphadenopathy. Which of the following changes in forced expiratory volume (FEV1) and forced vital capacity (FVC) would you expect to see if she takes a pulmonary function test?

A. FEV1 decreased; FVC decreased

B. FEV1 decreased; FVC no change

C. FEV1 decreased; FVC increased

D. FEV1 no change; FVC no change

E. FEV1 no change; FVC decreased

EXPLANATION:

Correct Answer A: FEV1 decreased; FVC decreased. This woman's presentation is consistent with sarcoidosis, an autoimmune disease that is characterized by noncaseating granulomas, especially in the lungs. Patients can present with dyspnea, fatigue, intermittent fevers, night sweats, weight loss, skin lesions (erythema nodosum), uveitis, hepatitis, and anemia. Bilateral hilar lymphadenopathy is commonly seen on chest X-ray. African American women, particularly nonsmokers, have the highest incidence of sarcoidosis.

This interstitial lung disease produces a restrictive pattern on pulmonary function tests (PFTs), which are abnormal in 40–70% of patients with stage II to IV disease. Diffusing capacity for carbon monoxide (DLCO) is reduced in advanced disease. All lung volumes are decreased and forced expiratory volume in the first second (FEV1) is decreased. However, the FEV1/ FVC (forced vital capacity) ratio is often normal because FEV1 and FVC are both decreased. If the FEV1/FVC ratio is normal, a low FVC indicated a restrictive pattern, whereas a normal FVC indicates a normal pattern.

Option B: As sarcoidosis is a restrictive lung disease, all the measurable lung volumes and capacities are decreased. FVC is the volume of air that can be forcefully exhaled after a maximal inspiration.

Option C: FVC is decreased in restrictive lung disease, not increased. FVC represents the maximum volume of air that can be inspired and then expired.

Option D: The FEV1:FVC ratio might remain normal in restrictive lung diseases, but the individual parameters would be decreased.

Option E: FEV1 is a measure of lung function. It is always decreased in lung disease.

Learning objective: Sarcoidosis is an autoimmune disease that produces a restrictive pattern of lung disease. All lung volumes, including FVC and FEV1, are reduced in restrictive lung diseases, but the FEV1: FVC ratio may be normal.

5. A 60-year-old woman presents to the clinic with a three month history of shortness of breath that worsens on exertion. She also complains of a chronic cough that has lasted for 10 years. Her symptoms are worsened even with light activities like climbing up a flight of stairs. She denies any weight loss, lightheadedness, or fever. Her medical history is significant for hypertension, for which she takes amlodipine daily. She has a 70-pack-year history of cigarette smoking and drinks 3–4 alcoholic beverages per week. Her blood pressure today is 128/84 mm Hg. A chest X-ray shows flattening of the diaphragm bilaterally. Physical examination is notable for coarse wheezing bilaterally. Which of the following is likely to be seen with pulmonary function testing?

A. Increased FEV1: FVC and decreased total lung capacity

B. Decreased FEV1: FVC and increased total lung capacity

C. Increased FEV1: FVC and normal total lung capacity

D. Decreased FEV1: FVC and decreased total lung capacity

E. Normal FEV1: FVC and decreased total lung capacity

EXPLANATION:

Correct Answer B: Decreased FEV1: FVC and increased total lung capacity. Dyspnea on exertion, history of smoking, chronic cough, and a flattened diaphragm on chest X-ray all suggest a diagnosis of chronic obstructive pulmonary disease (COPD). In patients with COPD, the FEV1: FVC ratio (forced expiratory volume in the 1st second: forced vital capacity) is decreased due to airway narrowing while the total lung capacity is increased due to air trapping. Obstructive lung diseases, such as COPD, bronchiectasis, and asthma, are characterized by airway obstruction, usually in the bronchioles which are lined with smooth muscle.

Option A: This is a typical pattern seen in restrictive lung diseases. An increased FEV1: FVC ratio can be seen in restrictive lung diseases because the decrease in FVC is greater than the drop in FEV1. Furthermore, the total lung capacity is always decreased in restrictive lung disease because lung expansion is diminished, which leads to decreased lung volumes.

Causes of restrictive lung disease

Intrinsic causes: • Pneumoconiosis/asbestosis • Radiation fibrosis • Drugs (amiodarone, bleomycin, and methotrexate) • Hypersensitivity pneumonitis • Acute respiratory distress syndrome (ARDS) • Infant respiratory distress syndrome • Tuberculosis • Idiopathic pulmonary fibrosis • Idiopathic interstitial pneumonia • Sarcoidosis
Extrinsic causes: • Lymphangioleiomyomatosis • Pulmonary Langerhans cell histiocytosis • Pulmonary alveolar proteinosis • Malformations of the thoracic cage (kyphosis, pectus carinatum, and pectus excavatum) • Obesity • Diaphragmatic hernia • Ascites • Pleural thickening

Option C: An increased FEV1: FVC ratio indicates restrictive lung disease, but it is unlikely for total lung capacity to be normal in such a case.

Option D: A decreased FEV1: FVC ratio indicates an obstructive lung disease while a decrease in total lung capacity is seen in restrictive lung disease. It is unlikely that they coexist.

Option E: A normal FEV1: FVC ratio can be seen in restrictive lung diseases as both FEV1 and FVC are reduced. Total lung capacity is always decreased in restrictive lung diseases.

Learning objective: The FEV1: FVC ratio can be used to differentiate between obstructive and restrictive lung diseases. It is usually decreased in obstruction and increased in restrictive lung disease.

6. A 48-year-old man seeks evaluation at a clinic with a complaint of breathlessness for the past couple of weeks. He says that he finds it difficult to walk a few blocks and has to rest. He also complains of cough for the past 3 months, which is dry and hacking in nature. The medical history is relevant for an idiopathic arrhythmia for which he has

been taking amiodarone daily fro the past year. He is a non-smoker and does not drink alcohol. He denies any use of illicit drugs. The vital signs are as follows: heart rate 98/min, respiratory rate 16/min, temperature 37.6°C (99.68°F), and blood pressure 132/70 mm Hg. The physical examination is significant for inspiratory crackles over the lung bases. An echocardiogram shows a normal ejection fraction. A chest radiograph is performed and is shown below. Which of the following findings will most likely be noted on spirometry?



A. Decreased FEV1 and normal FVC

B. Decreased FEV1 and FVC with decreased FEV1/FVC ratio

C. Normal FEV1 and FVC

<u>D. Decreased FEV1 and FVC with normal FEV1/FVC ratio</u>

E. Increased FEV1 and FVC

EXPLANATION:

<u>Correct answer D:</u> FVC or forced vital capacity is the volume of air that can be exhaled after a maximal inspiration. FEV1 or forced expiratory volume in the first second is the volume of air that can be exhaled in the first second of forced maximal expiration. The FEV1/FVC ratio is approximately 0.80 in healthy patients.

This patient with breathlessness and cough, inspiratory crackles on lung auscultation, and a history of amiodarone therapy most likely has drug-induced pulmonary fibrosis. The chest X-ray shows bilateral fibrosis. In restrictive pulmonary diseases, such as pulmonary fibrosis, both FEV1 and FVC are decreased proportionately; thus, FEV1/FVC is normal, while in some cases FEV1/FVC may be increased.

Long-term use of amiodarone may cause pulmonary toxicity—typically chronic interstitial pneumonitis and fibrosis, but the incidence only occurs in ~2% of patients today, which is much lower than in the past, since lower doses are used and monitoring programs are in place. Toxicity correlates with the total cumulative dose but rare exceptions occur, with toxicity developing after only 2–3 weeks of therapy.

A nonproductive cough and dyspnea are present in most patients with pulmonary toxicity and may be accompanied by pleuritic pain, weight loss, fever, and malaise. The chest examination often reveals bilateral inspiratory crackles.



Chest X-ray showing diffuse pulmonary fibrosis. Image: by James Heilman. License: CC BY-SA 3.0, modified by Lecturio

Option A: Pulmonary fibrosis is a restrictive pulmonary disease; thus, both FEV1 and FVC are decreased.

Option B: In restrictive pulmonary diseases, such as pulmonary fibrosis, FEV1/FVC is normal or increased because both FEV1 and FVC are proportionately decreased.

Option C: This patient has pulmonary fibrosis, which is a restrictive pulmonary disease, making it unlikely for him to have a normal FEV1 and FVC.

Option E: This patient has restrictive pulmonary disease, which decreases the likelihood of having a high pulmonary capacity.

Learning objective: Amiodarone may cause pulmonary fibrosis, which is a restrictive lung disease, in which both FEV1 and FVC tend to be decreased, making FEV1/FVC normal or even increased.

7. A 5-year-old boy is brought to the emergency department by his mother for a 3-hour history of cough and difficulty breathing. He was diagnosed with asthma last year but has only required albuterol nebulizer treatments about twice per month. Today his cough is accompanied by prominent wheezing, and the nebulizer has not helped. On examination, the child appears lethargic. His trachea slightly deviates to the right, and auscultation reveals diminished breath sounds with unilateral wheezing on the right. Which of the following pulmonary flow-volume loops best represents this patient’s most likely condition?



Image by Lecturio

A. Chart A

B. Chart B

C. Chart C

D. Chart D

E. Chart E

F. Chart F

G. Chart G

H. Chart H

EXPLANATION:

Correct Answer G: This patient most likely has an airway obstruction at the right mainstem bronchus. He has the classic triad of cough, unilateral wheezing, and diminished breath sounds plus tracheal deviation. Young children are often at risk for airway obstruction due to accidental foreign body inhalation as they tend to place small items in their mouths and often cannot express their problems. This patient's medical history led the mother to assume this incident was an asthma exacerbation rather than an inhaled foreign body which delayed seeking medical attention.

Flow-volume loops are used to graphically represent pulmonary spirometry findings. The images below correspond to each of the answer choices given. With unilateral bronchial obstruction, the spirometry finding reflects the single fully functioning lung and one that is at least partially obstructed. The vital capacity, represented by the horizontal length of the volume, is decreased by 50%, and the airflow is diminished showing flow limitation. The shape of the pressure-flow loop is preserved because the functional lung is working normally. However, the affected lung would show a flattened expiratory limb and a possible flattened inspiratory limb.



UAO = upper airway obstruction. RV Volume (L) is the residual volume (volume of air remaining in the chest after maximal exhalation) in liters. Image by Lecturio

Option A: This is the normal flow-volume curve. It is a plot of airflow against volume.

Option B: Emphysema is an obstructive lung disease that involves impairment in the expiratory flow and a generally normal vital capacity. The curve shown typifies an obstructive lung disease pattern as seen in the diminished expiratory flow, which is not as severe in mild disease. This patient also has underlying asthma, but he likely would have a fairly normal spirometry pattern considering his young age and mild disease.

Option C: This pattern is typical of restrictive lung disease. Lung volumes are decreased and flow is proportionally diminished. Causes of restrictive lung diseases are asbestosis, radiation fibrosis, sarcoidosis, and Langerhans cell histiocytosis.

Option D: Fixed upper airway obstruction can be caused by tracheal strictures (a potential complication following intubation), goiter, or tracheal tumors. As the obstruction is constant, it results in a flattening of the flow portion of the flow-volume curve. Lung volumes are usually normal.

Options E and F: Tracheomalacia, tumors, or vocal cord paralysis can lead to variable airflow obstruction. The occurrence of obstruction during the inspiratory or expiratory phase will flatten the corresponding section of the flow-volume curve.

Option H: Neuromuscular weakness results in the small globular shape of the pulmonary flow-volume loop.

Learning Objective: Flow-volume loops represent pulmonary spirometry findings graphically, and certain patterns can be seen in various types of lung diseases. Unilateral bronchus obstruction results in changes to pulmonary function, reflecting the function of a single lung. The obstructive process causes limited flow on the flow-volume loop. If the question stem were analyzing both lungs, then a flattened expiratory and or inspiratory loop would be considered in the flow-volume loop.

8. A 62-year-old man presents to the emergency department for shortness of breath, which started two years ago but has worsened in the last few months. He admits to a chronic cough and some mucous production in the mornings but denies fever. He says that he becomes more short of breath with exertion, but denies chest discomfort or peripheral edema. His past medical history is significant for hypertension, for which he takes chlorthalidone. He has a 40-pack-year smoking history. His blood pressure is 125/78 mm Hg, pulse is 90/min, and respiratory rate is 18/min. He is afebrile, and his pulse oximetry on room air shows an oxygen saturation of 94%. His body mass index (BMI) is 31 kg/m2. Pulmonary examination reveals decreased breath sounds

bilaterally, with no wheezes or crackles. The remainder of his physical examination is unremarkable. A chest radiograph shows hyperinflation of both lungs with mildly increased lung markings, but no focal findings. Which of the following would you expect to see, considering this man's presenting history, examination, and chest radiograph?

A. *FEV1/FVC of 60%*

B. Decreased total lung capacity

C. Increased DLCO

D. Metabolic acidosis

E. FEV1/FVC of 80% with an FEV1 of 82%

EXPLANATION:

Correct Answer A: FEV1/FVC of 60%. Clinical findings and the history of smoking in this man suggest a diagnosis of chronic obstructive pulmonary disease (COPD). COPD is an obstructive lung disease and consists of chronic bronchitis and emphysema (see image). Hyperinflation of the lungs on chest X-ray is suggestive of air trapping due to increased lung compliance, which is a result of emphysema.



Image: Chronic bronchitis and emphysema in COPD. By Lecturio

When noxious cigarette ingredients infiltrate the innate respiratory defenses of the epithelial cell barrier of the lung, they are transported to the bronchus-associated lymphoid tissue (BALT) layer, where they stimulate the release of neutrophil chemotactic factor. Macrophages release proteolytic enzymes (matrix metalloproteinases, or MMPs), which lead to the destruction of the epithelial barrier of the lung.

When a diagnosis of COPD is suspected, spirometry is performed pre-and post-bronchodilator administration to confirm the diagnosis. Airway obstruction that is irreversible or only partially reversible with a bronchodilator confirms the diagnosis of COPD. The forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) ratio is used to assess airway obstruction; a value of less than 70% (the lower limit of normal) is consistent with airflow obstruction.

Option B: Due to air trapping and hyperinflation, the total lung capacity is increased with COPD, not decreased.

Option C: The diffusing capacity of carbon monoxide (DLCO) is an excellent index of the degree of anatomic emphysema in smokers with airflow limitation, but is not needed for routine assessment of COPD. The DLCO decreases in proportion to the severity of emphysema.

Option D: Patients with COPD have respiratory acidosis due to retention of carbon dioxide, with compensatory metabolic alkalosis.

Option E: FEV1 is the volume of air that can be exhaled in the first second after full inspiration. Values between 80% and 120% are considered to be normal as long as the FEV1/FVC ratio is greater than 70%.

Learning objective: The FEV1/FVC ratio is used to assess airway obstruction; a value of less than 70% is abnormal.

9. A 50-year-old man is evaluated for a 2-year history of an intermittent, nonproductive cough, as well as for mild dyspnea with exertion. He has a 20-pack-year history of smoking and is a current smoker. His medical history is significant for hypertension and type 2 diabetes mellitus, which he has controlled with diet and exercise. He also takes lisinopril. On physical examination, his blood pressure is 125/76 mm Hg, his pulse rate is 78/min, his respiratory rate is 16/min, his oxygen saturation is 98% on room air, and his BMI is 25 kg/m2. There is no jugular venous distention. His

heart sounds are normal, and there is no murmur. Auscultation of the lungs reveals faint, bilateral wheezing. No peripheral edema is noted. The remainder of the examination is normal. Which of the following is most likely to confirm the diagnosis for this patient?

A. Chest CT scan

B. Measurement of protease inhibitor

C. Arterial blood gases

D. Spirometry

E. Cardiac catheterization

EXPLANATION:

Correct answer D: Based on the clinical findings and his history of smoking, this patient likely has chronic obstructive pulmonary disease (COPD) with emphysema. Spirometry is the preferred method for diagnosing this disease. FEV1/FVC of < 70% and FEV1 of < 80% of the predicted value confirmed the diagnosis.

There are generally 2 types of emphysema, centrilobular and panlobular emphysema, and they can be reliably distinguished on CT. Centrilobular emphysema is the most common type and is often found in asymptomatic elderly patients. Emphysematous changes are localized at the proximal respiratory bronchioles, particularly of the upper zones of the lung. Centrilobular emphysema is strongly associated with smoking. In contrast, panlobular emphysema affects the entire pulmonary lobule and is often found in the lower zones of the lung. This type of emphysema is associated with alpha-1-antitrypsin (A1AT) deficiency, which can be exacerbated by environmental pollutants and smoking.

Option A: CT can be performed to evaluate abnormalities seen on a conventional chest radiograph in order to exclude certain complications of COPD (e.g., thromboembolic disease and lung cancer). CT is also useful when a patient is being considered for lung volume reduction surgery or lung transplantation. It is not used to confirm the diagnosis.

Option B: Measurement of protease inhibitor refers to the measurement of alpha-1-antitrypsin (A1AT). Deficiency of A1AT should be suspected in young individuals with emphysema (< 45 years) or in a nonsmoker with emphysema. A1AT deficiency also involves liver disease.

Option C: Arterial blood gases should be checked in most patients to assess the severity of the exacerbation of COPD and to establish a baseline from which improvement or deterioration can be measured. It is not commonly used to confirm the diagnosis of COPD.

Option E: Cardiac catheterization is frequently indicated in heart failure patients with acute cardiac ischemia (STEMI) or new-onset systolic dysfunction. It has no role in the diagnosis of COPD.

Learning objective: Emphysema is a major component of COPD. Centrilobular emphysema affects the proximal respiratory bronchioles, particularly of the upper zones of the lung, and has a strong association with smoking. Panlobular emphysema is associated with alpha-1-antitrypsin (A1AT) deficiency and affects the entire pulmonary lobule and is more pronounced in the lower zones of the lung.

10. A 24-year-old woman presents with episodic shortness of breath, chest tightness, and wheezing. She has noticed an increased frequency of such episodes during the spring season. She also has a history of urticaria. She has smoked a half pack of cigarettes per day over the past 5 years. Her mother also has similar symptoms. The physical examination is within normal limits. Which of the following findings is characteristic of her condition?

A. Decreased forced vital capacity (FVC) on pulmonary tests

B. Increased oxygen saturation

C. Chest X-ray showing hyperinflation

D. Decrease in forced expiratory volume in 1 second (FEV1) after methacholine

E. Paroxysmal nocturnal dyspnea

Explanation:

Correct answer D: The patient presents with bronchial asthma, as indicated by the episodic and seasonal nature of her symptoms, a personal history of urticaria (another type-I hypersensitivity), and a family history of probable asthma in her mother. Like chronic obstructive pulmonary disease (COPD), bronchial asthma is characterized by shortness of breath, wheezes, and decreased FEV1. However, in patients with asthma, the FEV1 tends to be reversible after a dose of an inhaled bronchodilator, such as albuterol, whereas in COPD, it is not. FEV1 stands for forced expiratory volume in 1 second. It is the volume of air that can be forcefully expelled in the first second, after maximum inspiration. FVC is forced vital capacity, which is the total amount of air exhaled.

Between episodes, the symptoms of asthma may be absent, and the physical examination may be normal. If the diagnosis of asthma is unclear, a methacholine challenge test can be used. A decrease in FEV1 of greater than 20% is diagnostic for asthma.



Image: Reversibility of asthma with bronchodilators. By Lecturio

Option A: Decreased FVC on pulmonary function tests occurs in both restrictive and obstructive lung diseases, including asthma. Therefore, it is not a characteristic finding. In restrictive conditions, FEV1 and FVC are reduced proportionately, so the FEV1/FVC ratio can be normal. With obstructive lung disease, FEV1 and FVC are reduced disproportionately, hence the FEV1/FVC ratio is decreased.

Option B: Oxygen saturation is decreased during an asthma exacerbation, not increased.

Option C: In patients with emphysema, a chest X-ray will show hyperinflation of the lungs. This is not seen with asthma.

Option E: Paroxysmal nocturnal dyspnea commonly occurs in patients with left-sided heart failure, which would be unlikely in an otherwise healthy 24-year-old woman.

Learning objective: In patients with bronchial asthma, FEV1 fluctuates. It increases with β-agonists and decreases with methacholine.

REFERENCES

1. Volodymyr P. Feketa, Marianna I. Nemesh., Olga S. Palamarchuk Human physiology for doctors. Київ: ТОВ «Інтерсервіс», 2019. 488 с.

2. Materials from Lecturio https://uzhnu.lecturio.com/

3. Mason, Robert J., et al. Murray and Nadel's textbook of respiratory medicine E-book: 2-volume set. Elsevier Health Sciences, 2010.

4. Lin K, Watkins B, Johnson T, et al: Screening for chronic obstructive pulmonary disease using spirometry: Summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 148:535–543, 2008.

5. Ferguson GT, Enright PL, Buist AS, et al: Office spirometry fo lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 117:1146–1161, 2000.

6. Venkateshiah SB, Ioachimescu OC, McCarthy K, et al: The utility of spirometry in diagnosing pulmonary restriction. Lung 186:19– 25, 2008.

7. Miller MR, Hankinson J, Brusasco V, et al: Standardisation of spirometry. Eur Respir J 26:319–338, 2005.